ispaghula husk + mebeverine hydrochloride: clinical use

Prescribing considerations

• Confirm symptoms are consistent with IBS and assess new, worsening or persistent symptoms.
• Ensure the patient can swallow safely and understands the need for adequate liquid.
• Consider sodium, potassium, aspartame and phenylalanine content where relevant.
• Use care in hepatic or renal impairment and cardiac disorders such as heart block.
• Occupational handling of ispaghula powder can cause sensitisation, particularly in atopic individuals.

Contraindications and cautions

• Hypersensitivity to ispaghula, mebeverine or an excipient.
• Sudden persistent change in bowel habit, undiagnosed rectal bleeding or failure to defecate after laxative use.
• Gastrointestinal stricture, oesophageal or cardia disease, ileus, intestinal paralysis or megacolon.
• Difficulty swallowing or throat disorders.
• Avoid during pregnancy; do not use while breastfeeding.

Monitoring

• Review bowel symptoms and investigate red flags or deterioration.
• Monitor for obstruction, impaction and adequate fluid intake.
• Review glycaemic control with diabetes treatments.
• Review thyroid response with thyroid hormones.
• Assess suspected hypersensitivity and stop future exposure if sensitisation is confirmed.

Clinical pharmacology

Ispaghula hydrates and swells in the bowel, increasing bulk and facilitating transit. Mebeverine is rapidly absorbed and extensively metabolised; its direct smooth-muscle antispasmodic action relieves gastrointestinal spasm without materially affecting normal motility.

Formulation and product differences

• The product is an orange-flavoured granule formulation supplied in unit-dose sachets and dispersed in water before use.
• It contains aspartame, sodium and potassium, which may matter in phenylketonuria, renal impairment or restricted electrolyte diets.
• Plain ispaghula and mebeverine-only preparations have different licences, precautions and pregnancy or breastfeeding advice.